Navigate Fool.com
Will CVD beat
the market?

Covance, Inc. (NYSE: CVD)

Community Rating: 3 Stars: Appealing

86.17 0.05 (0.06%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $85.65
Previous Close $86.12
Daily Range $85.37 - $86.45
52-Week Range $78.75 - $106.50
Market Cap $4.9B
P/E Ratio 27.17
Dividend (Yield) $0.00 (0.0%)
Volume 299,719
Average Daily Volume 377,209
Current FY EPS $3.82

How do you think CVD
will perform against the market?

Top CVD Bull/Bear Pitches


EldrehadsPicks (< 20)
Submitted February 29, 2008

Let’s face it, investing in drug developers isn’t easy. First, there’s the science risk – the chance that the company’s best drug prospect will fail somewhere during the arduous clinical trial and re … More

0 Replies Reply Report this Post

epumple (3.05)
Submitted June 26, 2008

Covance is notorious for its cruel treatment of its laboratory animals and is the subject of a major campaign by Peta. Unlike most industries that use animals, Covance ha … More

5 Replies Reply Report this Post

News & Commentary Rss Feed

Is This Stock the Next Tax-Fleeing Takeout?

Icon Plc (ICLR) operates in the fast growing drug R&D industry and its tax friendly Irish address may make it an attractive acquisition target for larger peers like Quintiles (Q) or Covance (CVD)

Covance (CVD) Shares Cross Below 200 DMA

4 Disruptive Stocks Biotechs Depend On

Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.

Covance profit beats estimates as late-stage drug trials shine

Drug Development Goes Global in 2014

Contract research organizations like Quintiles (Q), Parexel (PRXL), and Covance (CVD) are growing as big pharma pumps up pipelines to offset the patent cliff.

Healthcare Stocks Trimming Today's Advance; Covance Authorizes $100-Mln Stock Buyback Program

Sector Update: Healthcare

Worried About Obamacare? Invest in This Sector Instead

Looking for health-care exposure in your portfolio, but want to steer clear of the Obamacare debate? Then this little-known health-care industry could be the answer.

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

Covance Beats on the Top and Bottom Lines

Central lab services and clinical development programs boost efforts of contract services provider.

See More CVD News...




Healthcare Information Services

Covance, Inc. (CVD) Description

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. Website: http://www.covance.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks